[
  {
    "ts": null,
    "headline": "S&P 500 Gains and Losses Today: Apple Stock Climbs; Eli Lilly Slumps After Disappointing Trial Results",
    "summary": "The S&P 500 slid 0.1% on Thursday, Aug. 7, 2025, as new tariffs took effect, raising import duties on goods from numerous U.S. trading partners.",
    "url": "https://finnhub.io/api/news?id=93c8069705b619910910891d87a9d565f295fefafa6589c5aee326ff82601e4c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754601789,
      "headline": "S&P 500 Gains and Losses Today: Apple Stock Climbs; Eli Lilly Slumps After Disappointing Trial Results",
      "id": 136266308,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PODD",
      "source": "Yahoo",
      "summary": "The S&P 500 slid 0.1% on Thursday, Aug. 7, 2025, as new tariffs took effect, raising import duties on goods from numerous U.S. trading partners.",
      "url": "https://finnhub.io/api/news?id=93c8069705b619910910891d87a9d565f295fefafa6589c5aee326ff82601e4c"
    }
  },
  {
    "ts": null,
    "headline": "Insulet (NASDAQ:PODD) Beats Expectations in Strong Q2, Stock Soars",
    "summary": "Insulin delivery company Insulet Corporation (NASDAQ:PODD) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 32.9% year on year to $649.1 million. On top of that, next quarter’s revenue guidance ($671.7 million at the midpoint) was surprisingly good and 4.4% above what analysts were expecting. Its non-GAAP profit of $1.17 per share was 26.8% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=767b94701e2626be1822aa5989836bf6b69c23f3f1dc2ed37d17d0d620391ea2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754589674,
      "headline": "Insulet (NASDAQ:PODD) Beats Expectations in Strong Q2, Stock Soars",
      "id": 136267934,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PODD",
      "source": "Yahoo",
      "summary": "Insulin delivery company Insulet Corporation (NASDAQ:PODD) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 32.9% year on year to $649.1 million. On top of that, next quarter’s revenue guidance ($671.7 million at the midpoint) was surprisingly good and 4.4% above what analysts were expecting. Its non-GAAP profit of $1.17 per share was 26.8% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=767b94701e2626be1822aa5989836bf6b69c23f3f1dc2ed37d17d0d620391ea2"
    }
  },
  {
    "ts": null,
    "headline": "Insulet Peer Tandem Diabetes Underwhelming Earnings, Dull Outlook Drags Stock",
    "summary": "Tandem Diabetes Care Inc.’s (NASDAQ:TNDM) stock plunged on Thursday after the company cut its annual guidance. The diabetes-focused company reported adjusted loss of 78 cents per share, missing the consensus loss of 40 cents. Tandem reported sales of $240.678 million, up 8% year over year, beating the consensus of $238.57 million. Shipments in the United States grew to approximately 21,000 pumps. Shipments outside the United States were approximately 9,000 pumps. Also Read: Goldman Sachs Bullish",
    "url": "https://finnhub.io/api/news?id=3e465c5e7f9c6f1123109f3029e8bfb1a7ee8df58335eeaae5a22a4090a21c58",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754589014,
      "headline": "Insulet Peer Tandem Diabetes Underwhelming Earnings, Dull Outlook Drags Stock",
      "id": 136267935,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PODD",
      "source": "Yahoo",
      "summary": "Tandem Diabetes Care Inc.’s (NASDAQ:TNDM) stock plunged on Thursday after the company cut its annual guidance. The diabetes-focused company reported adjusted loss of 78 cents per share, missing the consensus loss of 40 cents. Tandem reported sales of $240.678 million, up 8% year over year, beating the consensus of $238.57 million. Shipments in the United States grew to approximately 21,000 pumps. Shipments outside the United States were approximately 9,000 pumps. Also Read: Goldman Sachs Bullish",
      "url": "https://finnhub.io/api/news?id=3e465c5e7f9c6f1123109f3029e8bfb1a7ee8df58335eeaae5a22a4090a21c58"
    }
  },
  {
    "ts": null,
    "headline": "Insulet Corp. stock outperforms competitors on strong trading day",
    "summary": "Insulet Corp. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=f62915e9feeec1265f16a3fd5ed95de90ec5823cf3f32ec6fb2952c837fe3e55",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754584200,
      "headline": "Insulet Corp. stock outperforms competitors on strong trading day",
      "id": 136309386,
      "image": "",
      "related": "PODD",
      "source": "MarketWatch",
      "summary": "Insulet Corp. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=f62915e9feeec1265f16a3fd5ed95de90ec5823cf3f32ec6fb2952c837fe3e55"
    }
  },
  {
    "ts": null,
    "headline": "Insulet Pops As Diabetes Medtech Continues Its Streak Of 'Impressive Beat-And-Raises'",
    "summary": "Insulet Pops As Diabetes Medtech Continues Its Streak Of 'Impressive Beat-And-Raises'",
    "url": "https://finnhub.io/api/news?id=3b69a04ae4dcb6439a82f34f8be2d767770021c2516e7a06c1e970da46ff7216",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754583510,
      "headline": "Insulet Pops As Diabetes Medtech Continues Its Streak Of 'Impressive Beat-And-Raises'",
      "id": 136309361,
      "image": "",
      "related": "PODD",
      "source": "DowJones",
      "summary": "Insulet Pops As Diabetes Medtech Continues Its Streak Of 'Impressive Beat-And-Raises'",
      "url": "https://finnhub.io/api/news?id=3b69a04ae4dcb6439a82f34f8be2d767770021c2516e7a06c1e970da46ff7216"
    }
  },
  {
    "ts": null,
    "headline": "Insulet (PODD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates",
    "summary": "While the top- and bottom-line numbers for Insulet (PODD) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",
    "url": "https://finnhub.io/api/news?id=a61ece6e7a611eccd22f2d161135b7c2214970ba5da5cc5889b98daa5685ab64",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754573405,
      "headline": "Insulet (PODD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates",
      "id": 136267936,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PODD",
      "source": "Yahoo",
      "summary": "While the top- and bottom-line numbers for Insulet (PODD) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",
      "url": "https://finnhub.io/api/news?id=a61ece6e7a611eccd22f2d161135b7c2214970ba5da5cc5889b98daa5685ab64"
    }
  },
  {
    "ts": null,
    "headline": "Insulet beats second-quarter profit estimates on strong demand for insulin pumps",
    "summary": "Insulet has been benefiting from the expanded approval for its automated insulin delivery device, Omnipod, which offers a convenient alternative to conventional pumps with external tubing by eliminating the need for multiple daily injections for people with insulin-dependent diabetes.  Its Omnipod 5 device was cleared for use in both type 1 and type 2 diabetes patients last year.  The company now expects its annual revenue to grow in the range of 24% to 27% from a year earlier, compared with its previous projection of 19% to 22%, betting on strong demand for Omnipod 5.",
    "url": "https://finnhub.io/api/news?id=0c9d8bfd7c2996020ae84a769f6aaaedb6f789f10f6e3ed87770d14e8bb9e54c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754570381,
      "headline": "Insulet beats second-quarter profit estimates on strong demand for insulin pumps",
      "id": 136246881,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PODD",
      "source": "Yahoo",
      "summary": "Insulet has been benefiting from the expanded approval for its automated insulin delivery device, Omnipod, which offers a convenient alternative to conventional pumps with external tubing by eliminating the need for multiple daily injections for people with insulin-dependent diabetes.  Its Omnipod 5 device was cleared for use in both type 1 and type 2 diabetes patients last year.  The company now expects its annual revenue to grow in the range of 24% to 27% from a year earlier, compared with its previous projection of 19% to 22%, betting on strong demand for Omnipod 5.",
      "url": "https://finnhub.io/api/news?id=0c9d8bfd7c2996020ae84a769f6aaaedb6f789f10f6e3ed87770d14e8bb9e54c"
    }
  },
  {
    "ts": null,
    "headline": "Insulet (PODD) Surpasses Q2 Earnings and Revenue Estimates",
    "summary": "Insulet (PODD) delivered earnings and revenue surprises of +25.81% and +5.46%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finnhub.io/api/news?id=445d2f313edbdcf04e9622966f2875b8505e72f917d42d2d6347448c4f170103",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754568903,
      "headline": "Insulet (PODD) Surpasses Q2 Earnings and Revenue Estimates",
      "id": 136267937,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PODD",
      "source": "Yahoo",
      "summary": "Insulet (PODD) delivered earnings and revenue surprises of +25.81% and +5.46%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?",
      "url": "https://finnhub.io/api/news?id=445d2f313edbdcf04e9622966f2875b8505e72f917d42d2d6347448c4f170103"
    }
  },
  {
    "ts": null,
    "headline": "Insulet Corporation (PODD) Q2 2025 Earnings Call Transcript",
    "summary": "Insulet Corporation (NASDAQ:PODD) Q2 2025 Earnings Call August 7, 2025 8:00 AM ETCompany ParticipantsAna Maria Chadwick - Executive VP &amp; CFOAshley A.",
    "url": "https://finnhub.io/api/news?id=ea4e9650275c95f9a56b73bcc73c5a3296fa1765040d9adcd5f2c362f1245716",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754565256,
      "headline": "Insulet Corporation (PODD) Q2 2025 Earnings Call Transcript",
      "id": 136249286,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "PODD",
      "source": "SeekingAlpha",
      "summary": "Insulet Corporation (NASDAQ:PODD) Q2 2025 Earnings Call August 7, 2025 8:00 AM ETCompany ParticipantsAna Maria Chadwick - Executive VP &amp; CFOAshley A.",
      "url": "https://finnhub.io/api/news?id=ea4e9650275c95f9a56b73bcc73c5a3296fa1765040d9adcd5f2c362f1245716"
    }
  },
  {
    "ts": null,
    "headline": "Insulet: Q2 Earnings Snapshot",
    "summary": "ACTON, Mass. AP) — Insulet Corp. PODD) on Thursday reported second-quarter earnings of $22.5 million.",
    "url": "https://finnhub.io/api/news?id=5a025aa6da65b181402d9057a5d1b7cd8ee1cc593637dcadabace76676973453",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754565237,
      "headline": "Insulet: Q2 Earnings Snapshot",
      "id": 136246882,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PODD",
      "source": "Yahoo",
      "summary": "ACTON, Mass. AP) — Insulet Corp. PODD) on Thursday reported second-quarter earnings of $22.5 million.",
      "url": "https://finnhub.io/api/news?id=5a025aa6da65b181402d9057a5d1b7cd8ee1cc593637dcadabace76676973453"
    }
  },
  {
    "ts": null,
    "headline": "Insulet Reports Second Quarter 2025 Revenue Increase of 32.9% Year-Over-Year (31.3% Constant Currency1)",
    "summary": "ACTON, Mass., August 07, 2025--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended June 30, 2025.",
    "url": "https://finnhub.io/api/news?id=751bc83184d97be55aa8d6d59662dd384f19b5765759395420874c29d2a525b4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754564400,
      "headline": "Insulet Reports Second Quarter 2025 Revenue Increase of 32.9% Year-Over-Year (31.3% Constant Currency1)",
      "id": 136246883,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PODD",
      "source": "Yahoo",
      "summary": "ACTON, Mass., August 07, 2025--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended June 30, 2025.",
      "url": "https://finnhub.io/api/news?id=751bc83184d97be55aa8d6d59662dd384f19b5765759395420874c29d2a525b4"
    }
  }
]